Thao Nguyen Vu

Thao Nguyen Vu

Auto-generated profile, based on publicly available information

Thao Nguyen Vu

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Virus Research
Verified
Journal Article
Open access
TVThao Nguyen Vu
Thao Nguyen Vu
JCJustin Ryan Clark
Justin Ryan Clark
EJEris Jang
Eris Jang
RDRoshan D'SOuza
Roshan D'SOuza
LNLe Phuong Nguyen
Le Phuong Nguyen
DYDongeun Yong
Dongeun Yong
• Appelmans protocol broadens host range of a phage cocktail targeting acinetobacter baumannii. • Prophage induction and recombination contributes to the broadening of the phage cocktail host range. • Recombination of prophages from encountered bacterial strains generates expanded host range phages. • Induced phages demonstrated limited stability, unsuitable for therapy.

20 May 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
LNLe Phuong Nguyen
Le Phuong Nguyen
NPNaina Pinto
Naina Pinto
TVThao Nguyen Vu
Thao Nguyen Vu
HLHyunsook Lee
Hyunsook Lee
YCYoung Lag Cho
Young Lag Cho
DYDongeun Yong
Dongeun Yong
This study investigates GT-1 (also known as LCB10-0200), a novel-siderophore cephalosporin, inhibited multidrug-resistant (MDR) Gram-negative pathogen, via a Trojan horse strategy exploiting iron-uptake systems. We investigated GT-1 activity and the role of siderophore uptake systems, and the combination of GT-1 and a non-β-lactam β-lactamase inhibitor (BLI) of diazabicyclooctane, GT-055, (also referred to as LCB18-055) against molecularly characterised resistant Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. isolates. GT-1 and GT-1/GT-055 were tested in vitro against comparators among three different characterised panel strain sets. Bacterial resistome and siderophore uptake systems were characterised to elucidate the genetic basis for GT-1 minimum inhibitory concentrations (MICs). GT-1 exhibited in vitro activity (≤2 μg/mL MICs) against many MDR isolates, including extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing E. coli and K. pneumoniae and oxacillinase (OXA)-producing Acinetobacter spp. GT-1 also inhibited strains with mutated siderophore transporters and porins. Although BLI GT-055 exhibited intrinsic activity (MIC 2–8 μg/mL) against most E. coli and K. pneumoniae isolates, GT-055 enhanced the activity of GT-1 against many GT-1–resistant strains. Compared with CAZ-AVI, GT-1/GT-055 exhibited lower MICs against E. coli and K. pneumoniae isolates. GT-1 demonstrated potent in vitro activity against clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro activity of GT-1 against many GT-1–resistant strains.

1 January 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
TVThao Nguyen Vu
Thao Nguyen Vu
JBJung-Hyun Byun
Jung-Hyun Byun
RDRoshan D’sOuza
Roshan D’sOuza
NPNaina Pinto
Naina Pinto
LNLe Phuong Nguyen
Le Phuong Nguyen
YCYunsop Chong
Yunsop Chong
Vu TN, et al. Ann Lab Med. 2020 Jan;40(1):21-26. https://doi.org/10.3343/alm.2020.40.1.21

16 April 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LNLe Phuong Nguyen
Le Phuong Nguyen
CPChul Soon Park
Chul Soon Park
NPNaina Pinto
Naina Pinto
HLHyunsook Lee
Hyunsook Lee
HSHyun Soo Seo
Hyun Soo Seo
DYDongeun Yong
Dongeun Yong
The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant E. coli and K. pneumoniae, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant A. baumannii and P. aeruginosa at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing E. coli and K. pneumoniae, while LCB10-0200 alone was active against ADC-, OXA-, and VIM- producing A. baumannii and P. aeruginosa. Both LCB10-0200 and LCB10-0200/AVI displayed low activity against IMP- and NDM- producing strains. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae.

31 October 2019 in Pathogens
Verified
Journal Article
Open access
PDF file
LNLe Phuong Nguyen
Le Phuong Nguyen
NPNaina Pinto
Naina Pinto
TVThao Nguyen Vu
Thao Nguyen Vu
HMHung Mai
Hung Mai
APAn Ht Pham
An Ht Pham
DYDongeun Yong
Dongeun Yong
Recently, a blaNDM-9 and mcr-1 co-harboring E. coli ST 617 isolate was identified from an asymptomatic carrier in Korea. An 81-year-old female was admitted to a university hospital for aortic cardiac valve repair surgery. Following surgery, she was admitted to the intensive care unit (ICU) for three days, and carbapenem-resistant E. coli YMC/2017/02/MS631 was isolated from a surveillance culture (rectal swab). Antimicrobial susceptibility testing (AST) for colistin was not performed at that time. Upon retrospective study, further AST revealed resistance to all tested antibiotics, including meropenem, imipenem, ceftazidime-avibactam, amikacin, gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole, and colistin, with the exception of tigecycline. Whole genome sequencing analyses showed that this strain belonged to the ST617 serotype O89/162: H10 and harbored three β-lactamase genes (blaTEM-1B, blaCTX-M-55, blaNDM-9), mcr-1, and 14 other resistance genes. Seven plasmid replicon types (IncB, IncFII, IncI2, IncN, IncY, IncR, IncX1) were identified. Horizontal transfer of blaNDM-9 and mcr-1 from donor cells to the recipient E. coli J53 has been observed. blaNDM-9 and mcr-1 were carried by IncB and IncI2 plasmids, respectively. To speculate on the incidence of this strain, routine rectal swab screening to identify asymptomatic carriers might be warranted, in addition to the screening of ICU patients.

19 January 2021 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
NPNaina Pinto
Naina Pinto
RDRoshan D'SOuza
Roshan D'SOuza
LNLe Phuong Nguyen
Le Phuong Nguyen
TVThao Nguyen Vu
Thao Nguyen Vu
DYDongeun Yong
Dongeun Yong
Evolution of multi-drug resistant bacteria has led to worldwide research to better understand the various resistance mechanisms in these strains. Every year, novel information on carbapenem resistance and its mechanisms is being discovered. In this study, radiation-mediated mutagenesis was used to transform a carbapenem-resistant Klebsiella pneumoniae strain to a carbapenem-susceptible bacterium. Through this process, we proved three conditions of loss of the OmpK35 and the OmpK36 genes and acquisition of blaCMY-10 worked together to produce carbapenem resistance in K. pneumoniae. Loss of only one of the porins did not evoke carbapenem resistance. This is the first report on the essential contribution of these three components of carbapenem resistance in K. pneumoniae.